Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia
- 3 May 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (10), 3661-3668
- https://doi.org/10.1021/jm101401a
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Metabolic manipulation of glycosylation disorders in humans and animal modelsSeminars in Cell & Developmental Biology, 2010
- Synthesis and evaluation of non-hydrolyzable d-mannose 6-phosphate surrogates reveal 6-deoxy-6-dicarboxymethyl-d-mannose as a new strong inhibitor of phosphomannose isomerasesBioorganic & Medicinal Chemistry, 2009
- Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patientsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- The relative contribution of mannose salvage pathways to glycosylation in PMI-deficient mouse embryonic fibroblast cellsThe FEBS Journal, 2008
- Genetic defects in the human glycomeNature Reviews Genetics, 2006
- Essentials of GlycosylationSeminars in Pediatric Neurology, 2005
- Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblastsGlycobiology, 2005
- Inhibition of Type I and Type II Phosphomannose Isomerases by the Reaction Intermediate Analogue 5-Phospho-d-Arabinonohydroxamic Acid Supports a Catalytic Role for the Metal CofactorBiochemistry, 2004
- A General and Efficient Copper Catalyst for the Amidation of Aryl HalidesJournal of the American Chemical Society, 2002
- Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.JCI Insight, 1998